Clozapine

1. 2. 3. Davis, Audrey. Bloodletting Instruments in the national Museum of History and Technology. City of Washington. Smithsonian Institution Press. 1979. p3-37. Fido, Martin. The World's Worst Medical Mistakes. Great Britain. Sevenoaks. 1996. p188-211. Flynn, John C. Procedures in Phlebotomy. Philadelphia. WB Saunders Co. 1994. p3-6. King, Lester S. A History of Medicine. Middlesex, England. Penguin Books. 1971. p193-201. McCall, Ruth E. Phlebotomy Essentials. Philadelphia. JB Lippincott Co. 1993. p2-4. Mettler, Cecilia. History of Medicine. Toronto, ON. The Blakiston Co. 1947. p48, 207, 328-9, 333-5, Pendergraph, Garland E. Handbook of Phlebotomy. Philadelphia. Lea & Febiger. 1988. p1-7. Porter, Roy. The Greatest Benefit to Mankind. London, England. HarperCollins Publishers. 1997. p75-7, 116, 149, 313-4. 8226; history or presence of severe psychiatric illness and or any addictions to drugs, medication or alcohol in the past 3 years, for example, action of clozapine. This was a phase-II, randomized, double-blind, active- and placebo-controlled, parallel-group study of pediatric patients with SAR conducted during the spring of 1996 at 20 centers in the US. All patients were required to have a history of SAR and to be symptomatic during that season. Patients were also required to have a positive response to skin testing for an aeroallergen prevalent during that season, documented by a positive response to either a skin prick test wheal diameter 3 mm larger than that induced by the diluent control ; or intradermal testing 7 mm larger than that induced by the diluent control ; . In addition, patients were free from any clinically significant disease other than SAR and were clinically symptomatic at both the screening and baseline visits; female patients were premenarchal. A washout period was required before screening for any patient who was using intranasal, ocular, oral, inhaled, or systemic medications for rhinitis symptoms. Prescreening medication washout periods were as follows: 12 to 48 hours for short-acting antihistamines.
In kilograms Dosage Table In the first four months of life. See PRECAUTIONS: Pediatric Use and mebeverine.
171 With such dumb blondes as Glenda Gray, Helen Rees and Charlene Smith calling the AIDS drug policy shots in South Africa, maybe Michael Moore should fly in and document their performance as his next project and call it Stupid White Women. He'd find no shortage of them in the virology faculties of our country's medical schools either. ; But seriously, having regard to the corpus of published AZT toxicity data drawn to Council's attention in our correspondence, we propose that any of its members still recommending the prescription of AZT to pregnant women and their newborn babies, mostly black, mostly poor, are equally ignorant, lazy, simple, corrupt or depraved. Dr Miklos Nyiszli, a Jewish pathologist interned at Auschwitz and forced to conduct autopsies on other prisoners killed by Dr Josef Mengele in the course of his Nazi medical experiments, described the sort: `Among all criminals and murderers, the most dangerous type is the criminal physician.' Since AZT has been shown to kill children exposed to it in the womb, and neurologically and otherwise seriously harm others, those intransigent members of Council, who, notwithstanding notice of the dreadful research data traversed in our correspondence, persist in putting the commercial interests of the pharmaceutical cartel and their own face above the safety of the South African public, might reflect on whether this cap fits them too. We look forward to Council's promised response to our letters, including our seventh. Be sure to pass this eighth one on too, please. Would you confirm that you have done so in writing? As we've mentioned, we expect having to go beyond Council's invested experts to set this mess straight. Because having ignorantly contradicted President Mbeki and Dr Tshabalala-Msimang on the dangerous toxicity of AZT in 1999 and 2000, particularly concerning its use in pregnancy, and then going on in July this year to actively recommend this despite the intervening accretion of so much appalling adverse data, we honestly don't think there's much hope that they'll be up to reversing themselves and publicly admitting that they have blundered big-time. Since who likes eating crow? Yours faithfully ADV ANTHONY BRINK CONVENER AND NATIONAL CHAIRMAN TREATMENT INFORMATION GROUP Cc: The South African government, all provincial Health MECs, media and other interested parties.

Of importance, treatment should be initiated with a sufficient subnauseating dose of medication at the onset of headache and combivir, because what is clozapine. 1994 Mental health services research through a public-academic liaison: a comparison of two case management models, in Proceedings of the First Annual Conference of the National Association ofState Mental Health Program Directors Research Institute. Arlington, Va, NASMHPD, 1990 chology.
Updated Information & Services References including high-resolution figures, can be found at: : pediatrics cgi content full 107 1 86 This article cites 16 articles, 2 of which you can access for free at: : pediatrics cgi content full 107 1 86#BIBL This article has been cited by 1 HighWire-hosted articles: : pediatrics cgi content full 107 1 86#otherarticles This article, along with others on similar topics, appears in the following collection s ; : Genitourinary Tract : pediatrics cgi collection genitourinary tract Information about reproducing this article in parts figures, tables ; or in its entirety can be found online at: : pediatrics misc Permissions.shtml Information about ordering reprints can be found online: : pediatrics misc reprints.shtml and lamivudine. When abuse escalates to this level, young people may go missing from school, home or work, endanger their health or get into legal trouble, levy said. Clozapine and quetiapine occupy about 30%, which may explain their low propensity to cause eps and zidovudine.
Atypical antipsychotics have, according to some, revolutionised the treatment of schizophrenia. These drugs are claimed to be better tolerated than older typical drugs largely because of their lower propensity to cause acute extrapyramidal side-effects EPSE ; . Some atypicals cause little or no hyperprolactinaemia. Some are suggested to cause less tardive dyskinesia than typical drugs. Many are claimed to improve, to a relatively greater extent, negative and cognitive symptoms of schizophrenia. In addition, one atypical, clozapine, is unarguably more effective than typical drugs in the treatment of refractory schizophrenia. Atypical drugs are now sometimes recommended as first choice treatment for schizophrenia Lieberman, 1996; Taylor et al, 2000 ; . Set against these positive views are the draft recommendations of the National Schizophrenia Guidelines Group of the Royal College of Psychiatrists. This group apparently suggests that typical drugs should be first choice agents Donnelly, 1999 ; on the basis that atypical drugs have only been compared with moderate or high doses of typical drugs and not with lower doses, which might be relatively better tolerated Bebbington, 1999 ; . The essence of this argument is that typical antipsychotics are effective and well-tolerated when used in low doses. In order to evaluate properly this interesting proposition, it is necessary to define very carefully the terms used. What is meant, for example, by `low doses'? Most trials of atypical drugs used for comparison fixed doses of haloperidol of 10 mg or 20 mg a day. Where dose titration was allowed, mean doses of haloperidol were between 10 mg and 20 mg day. `Low dose' therapy, therefore, is assumed to indicate a dose of less than 10 mg a day of haloperidol. `Effective' might be taken to mean unequivocally more effective than placebo as measured by recognised rating scales. `Well-tolerated' could be assumed to indicate placebo levels of EPSE, hyperprolactinaemia and tardive dyskinesia. Thus, the central question is this is there a dose of typical antipsychotic that is effective, but does not give rise to typical adverse effects? Additional complications to this conundrum are the doses of typical drugs used in practice and whether or not these reflect doses used in clinical trials. Alongside this, it is also important to consider the adverse effect burden induced by normal clinical use of typical drugs. That is, how toxic are atypicals when used in cliniciandetermined doses?.

Some studies indicate that the drug clozapine clozaril ; and quetiapine seroquel ; , normally used in schizophrenia, may be the optimal agents at this time to help offset the psychiatric side effects and compazine. Elevation. Caroff et al 2000 ; reviewed all NMS cases published related to atypical neuroleptics, and applied various diagnostic criteria sets retrospectively. They concluded that although all NMS cases associated with atypical antipsychotics met broad criteria for NMS, some patients present only with a partial or incomplete form of classic NMS such as lack of rigidity, fever, or other primary features. Nevertheless, they found most published cases of NMS associated with olanzapine and clozapine included prominent muscular rigidity. The standard approach to manage NMS includes recognizing the diagnosis early, excluding alternative causes of the symptoms, discontinuing suspected triggering drugs, and providing supportive care to reduce temperature, ensure fluid balance, and prevent complications Caroff 2003 ; . There is limited consensus and inconsistent evidence on the comparative efficacy of specific treatments for NMS. Davis et al 2000 ; concluded that, in view of heterogeneity of cases diagnosed as NMS, lack of prospective, controlled trials, and standardized dosing, it is difficult to consider any specific pharmacological intervention or electroconvulsive therapy ECT ; to be superior. Benzodiazepines have been recommended for managing agitation and reversing catatonic symptoms of NMS Fink 1996 ; . In some cases, benzodiazepines were found to be effective when other medications failed Miyaoko 1997 ; . Some workers have advocated benzodiazepines as specific treatments for NMS, based on clinical similarities between catatonia and NMS Fink 1996; Davis et al 2000; Francis et al 2000 ; . Francis el at 2000 ; reported robust resolution of NMS symptoms with high potency benzodiazepines in 16 patients meeting APA 1994 ; or Caroff-Mann 1993 ; criteria whose NMS was precipitated by typical antipsychotic agents. Muscular rigidity and fever abated in 2448 hours with lorazepam at daily doses of ~3 mg. Khaldarov 2000 ; reported two additional cases of NMS from typical antipsychotics that appeared to respond similarly to lorazepam treatment with prompt resolution of NMS. In the present three cases, NMS was precipitated by atypical neuroleptic agents. We employed a similar management in our three patients, using supportive care and lorazepam. Both fever and muscular rigidity improved and resolved in 2472 hours. These findings indicate that lorazepam may be useful for management of NMS precipitated by both typical and atypical antipsychotic agents.
Table 1: Antipsychotic switching strategies 3, 4 ; Advantages Lowest interaction potential Side-effects of the second drug are less likely to be confused with withdrawal effects of the first drug 5 ; Low interaction potential Required when the patient has had a serious adverse effect to the first drug e.g. blood dyscrasias with clozapine In general, the preferred method 6 ; Useful for switches from high potency antipsychotics to low potency antipsychotics Useful for switches where cholinergic rebound may occur Suitable if relapse prevention is of greatest concern Most appropriate if the patient has recently recovered from acute relapse with the first drug and prochlorperazine.
Line of defense against respiratory viruses. Induction of mucosal immunity is also the subject of investigation in the area of infections caused by intestinal flora. Specific detection methods for intestinal bacteria are developed using fluorescence in situ hybridisation with 16S rRNA targeted probes in order to analyze their role in disturbed ; intestinal homeostasis in inflammatory bowel ; disease. The mucosal IgA response against several commensal bacteria is studied in gnotobiological animals. Tumor immunology: Genetic and protein-based immunotherapeutic strategies are being explored in order to induce effective immune responses against Human Papillomavirus HPV ; -transformed cells. This includes both in vitro and clinical studies. For immunotargeting to tumor cells and tumor vasculature, bispecific antibodies and bifunctional therapeutic proteins are being developed and assessed for their therapeutic potential in in vitro and in vivo experimental systems. Furthermore, induction of apoptosis is subject of investigation with emphasis on the role of sphingolipids. A close collaboration with the program `Northern Netherlands Oncology Centre' NNOC ; warrants exchange of expertise and materials and ensures efficient implementation of preclinical findings into experimental clinical treatment settings. B.6.2.5 Methodology Research within TRIO starts from clinical questions and is therefore organised from bedside to bench and back bidirectional translational research ; . As such, the following methodology is used: In the clinical environment well-characterized cohorts of patients are prospectively followed according to defined protocols. This relates particularly to patients with end-stage organ failure kidney, pancreas, liver, lung and intestinal tract ; awaiting or having undergone transplantation, patients with systemic autoimmune diseases and vasculitis, and, in collaboration with the division NNOC, patients with cancer. Clinical data are prospectively stored in databases and used for assessing clinico-pathological correlations, mechanistic studies relating to pathophysiology, and analysis of treatment modalities. From these patients different materials such as plasma serum samples, blood cells, and tissue samples biopsies ; are stored for present and future studies aiming at elucidation of pathophysiological questions and specific treatment responses. Cohorts of patients are selected, among others based on their clinical profile as retrieved from stored clinical data for intervention studies single or multicentre studies ; . For some of these studies, the necessary GLP GMP GCP facilities have been initiated. In vivo experimental models are used for analysis of pathogenesis and assessment of new therapeutic modalities. Organ transplant models kidney lung in rats ; are being used to study chronic ; graft dysfunction. Transgenic rat models are developed for analysis of the pathogenesis of ANCA-associated vasculitis, and rat models of glomerulonephritis are used for specific targeting of anti-inflammatory drugs to the kidney. Transgenic rat and mouse models have been developed and are used as well for assessing anti-tumor responses with experimental anti-tumor constructs, and evaluation of novel vaccine formulations involving determination of systemic and mucosal antibody responses as well as cytotoxic T lymphocyte induction. Also, isolated perfusion models are available for experimental studies on graft preservation. Various methodological instruments are used in vitro to analyze pathophysiological pathways and to assess treatment responses, such as advanced flowcytometric analysis, cell culture techniques among others an endothelial cell culture facility ; , quantitative RT- ; PCR, ELISA, denaturing gradient gel electrophoresis, and other molecular biological and immunological methods. For quantitative monitoring of bacterial microbiotic composition fluorescence in situ hybridization with a large set of 16S rRNA-targeted probes using automated microscopy and image processing is applied. Molecular aspects of viral infection mechanisms, including structure-functions analysis of viral envelope glycoproteins, are being studied in in vitro model systems, involving fluorescently or radiolabeled recombinant ; virus preparations and artificial membrane vesicles as target membranes. In addition, viral infection pathways are being defined in cultured cell systems. For diagnosis, treatment and prevention vaccines ; production of recombinant proteins using prokaryotic and eukaryotic expression systems ; , monoclonal antibodies, bispecific antibodies and bifunctional proteins, antigen-loaded virosomes and recombinant viral vectors are, for example, clozapine package insert. Draft Another participant asserted that the treatment community needs to look at ethical issues and take a stand on the money that Pharma spends on detailing, education programs and grants, which contributes to why drugs are so expensive. The position paper also could address these ethical issues and the need to find other ways to finance education programs and other activities. One person reported that the Center for Evidenced-Based Policy is examining different classes of medication, systematically and objectively trying to identify differences among them. The Center is working with ten other states, including the state Medicaid office, to develop the study. However, the process has been slow, particularly as the pharmaceutical industry has been unwilling to share many of its studies. Until there is a broad registry of clinical drug trials available, any group that wants to evaluate drug efficacy will have limited data with which to work. Buying medications based on disease episodes also was discussed. Missouri has used that approach by funding slots for people on Clozapine. Mr. Hill's presentation indicated that the Federal government may need to be involved in the slot approach, so as to not to run afoul of Medicaid best price equivalent rules and risk litigation. The discussion prompted participants to think about the different public systems paying for psychiatric medications, and the challenge of maintaining continuity of care among the various systems. Dr. Parks added that states with political will can address this fragmentation issue. The challenge is figuring out how to build the necessary political will, perhaps another topic to be addressed in a Medical Directors Council position statement. Another participant asserted that, over the long term, drug companies cannot continue raising drug prices 17 percent per year. With Medicare paying a large part of the nation's medical bills, the government is going to become increasingly concerned about "free enterprise." He suggested that the Medical Directors Council needs to get ahead of the curve and argue for a system that provides the needed drugs to people in the public mental health system in a rational and cost-effective way. The drug companies market these drugs as equivalent, so why are there significant price differentials among them? The Council could start the debate with a position paper that lays out the broad framework for discussion. Finally, a participant discussed the push for evidence-based practices in the field, which is also relevant for the medication discussion. Noting that existing medication studies are not very strong, another participant cautioned that a close examination of the evidence base could lead to a "morass" and end up paralyzing the broader discussion about improved medication policy and practice. Given the strong interest in this topic, the group decided that the pricing discussion would continue during the Council's business meeting and coreg. FDA Intercenter Agreement between the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research Oct. 31, 1991 ; , reprinted in FDLI, 3 Food & Drug L Rep. No. 2, at 29 Supp. Feb. 1992 ; . FDA Intercenter Agreement between the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health Oct. 31, 1991 ; , reprinted in FDLI, 3 Food & Drug L Rep. No. 2, at 44 Supp. Feb. 1992. Diagnostic information. Hallucinations must be distinguished from delusions and from confabulation for diagnostic accuracy. Levy A. Pituitary disease: presentation, diagnosis, and management. J Neurol Neurosurg Psychiatry 2004; 75 suppl 3 ; : 4752 In this brief yet comprehensive overview, the presentation, classification, and general investigation of pituitary lesions are followed by a discussion of the diagnosis and management of specific secretory subtypes. Important general diagnostic maneuvers include use of magnetic resonance imaging, visual field examination, and assessment of hormone levels. Melkersson K, Hulting AL. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder. Eur Arch Psychiatry Clin Neurosci 2000; 250: 610 Three patients with psychoses and concomitant prolactin-secreting pituitary tumors are described. These case reports support the view that neuroleptics being dopamine antagonists ; and dopamine agonist agents, used as a primary treatment for prolactinomas, can cancel out the other's effects. The combination of cpozapine and quinagolide is recommended as the treatment of choice for patients with psychosis and a prolactinsecreting tumor. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002; 5: 5565 Medical therapy is the initial treatment of choice for patients with prolactinomas. When infertility is the primary indication for treatment, bromocriptine use has an extensive safety experience and is preferred. However, for other indications, cabergoline appears to be more efficacious and better tolerated. Transsphenoidal surgery remains an option, especially for patients with microadenomas, when medical therapy is ineffective. Parry TS. Assessment of developmental learning and behavioural problems in children and young people. Med J Aust 2005; 183: 4348 This article outlines the clinical approach to the assessment of pediatric patients with behavioral problems for developmental and learning disorders. Observation, careful history, and assessment of cognitive function provide most of the diagnostic information. A multidisciplinary team approach is recommended. Schlechte JA. Prolactinoma. N Engl J Med 2003; 349: 20352041 A comprehensive review article on the clinical etiologies, diagnosis, and treatment of prolactinomas. Using a case report of a 22-year-old woman with amenorrhea, galactorrhea, and an elevated prolactin level as an example, the article explains the rationale behind the clinical workup and describes the various options for the management of microadenomas and macroadenomas. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987; 48: 6771 To characterize the rate and prevalence of microprolactinoma growth, the authors performed serial computerized tomography scans an average of about 32 months apart ; in 38 untreated patients with microprolactinomas. In no patient was there any evidence of tumor growth. The authors conclude that the majority of patients with microprolactinomas have a benign course, with tumor growth occurring, if at all, over a period of years. Sonino N, Fava GA. Psychological aspects of endocrine disease. Clin Endocrinol Oxf ; 1998: 49: 17 This article highlights some ways that the psychosocial aspects of endocrine illness may have important clinical and research implications. Areas discussed include the role of life stress in the pathogenesis of some endocrine conditions, the association of psychosocial variables with affective disorders, and the presence of residual symptoms after treatment. Evidence points to the need for an updated psychosocial awareness of endocrine disease. Weitzner MA, Kanfer S, Booth-Jones M. Apathy and pituitary disease: it has nothing to do with depression. J Neuropsychiatry Clin Neurosci 2005; 17: 159166 The authors present a series of cases in which patients with pituitary disease were diagnosed and treated for depression with little response to conventional antidepressants. They note that there is a growing understanding that patients with pituitary disease may experience depressed mood and emotional withdrawal as a result of the long-term effects of the pituitary tumor itself, its treatment, and or the hormonal changes that occur on the hypothalamic-pituitary-endorgan axis. When the diagnosis of apathy syndrome was considered and treatment implemented, the patients' condition improved. A review of the literature on apathy, hypothalamic-pituitary-endorgan axis dysfunction, and treatment for apathy syndrome is included and losartan.

Essays, Medical Articles, Human Interest Stories & Cartoons. Contact Editor Sue Zizza for deadlines at 516 ; 483-8321.
WFSBP Guidelines for Biological Treatment of Schizophrenia quality of life. Therefore, in suspected TRS, the target symptoms should be precisely defined. Due to modified criteria in recent guidelines, treatment resistance is assumed if there is either no improvement at all or only insufficient improvement in the target symptoms, despite treatment at the recommended dosage for a duration of at least 6 8 weeks with at least two antipsychotics, one of which should be an atypical antipsychotic NICE 2002; APA 2004 ; . Compliance should be ensured, if necessary by checking drug concentrations. Efficacy of first-generation antipsychotics. There is only limited evidence for the efficacy of FGAs for TRS. A review summarizing more than 100 trials comparing two or more different FGAs concluded that only one study found any FGA to be more effective than another Janicak et al. 1993 ; . As a result, in terms of efficacy, FGAs were considered interchangeable Conley und Buchanan 1997 ; . In most controlled trials of FGAs in patients with drug-resistant symptoms, the percentage of responders was fewer than 5% Kane et al. 1988 ; or in the range of 3 7% Kinon et al. 1993 ; , changing the FGA once or twice if response failed. So the primary reason for choosing between drugs was to reduce side effects, provide different dosing strategies, or offer different routes of administration Conley und Buchanan 1997 ; . Based on neurobiochemical considerations, data from blocking 80 90% of D2 receptors by 400 mg CPZ equivalents e.g., Farde et al. 1992 ; and clinical impressions from acute treatment studies e.g., Baldessarini et al. 1988; Bollini et al. 1994; Dixon et al. 1995 ; suggested that higher dosages of FGA produce no therapeutic benefit for TRS, but led to a higher rate and severity of EPS and other disabling side effects Kane 1994; Moller 1996 ; . Efficacy of second-generation antipsychotics. A metaanalysis summarising 12 RCTs comparing the efficacy and tolerability of SGAs versus FGAs for TRS found that there were more favourable outcomes when treated with clozapne reflected by superior improvement in overall psychopathology, categorical response rate, EPS and adherence rate, and when treated with olanzapine with regard to categorical response and adherence rates Chakos et al. 2001 ; . The efficacy of clozaline for TRS could be underlined in a meta-analysis using Cochrane criteria Wahlbeck et al. 1999 ; and by evaluating all available 10 RCTs comparing clozapine to other antipsychotic agents in another meta-analysis NICE 2002 ; . In this review, six double-blind, randomised controlled studies in TRS lasting 6 52 weeks demonstrated superior efficacy in improvement of global psycho and crestor and clozapine.
Maintaining the previous maximum level of 800 g preformed vitamin A per daily dose Advantages: None observed Disadvantages: A large proportion of the population ingest more than 1500 g per day in total in the case of additional intake of 800 g retinol. Food supplements with this daily dose would not be suitable for children or adolescents because the UL for these age groups would largely be used up or would be exceeded in the higher percentiles see Table 7 in Annex 4.7. The individual analysing the data was blind regarding drug condition for each study day and rosuvastatin.
Federal and state records allowed researchers to collect clinical information and track prescription drug purchases. Another drug, clozapine, whose exact mode of action remains unclear relieves schizophrenic symptoms in some patients who are not helped by phenothiazines.
Put this funding toward ADAP. In the case of ADAP supplemental funding, states are required to provide a state match, but this generally represents a relatively small share $2.5 million, or less than one percent, in FY 2006 ; of state funding for ADAPs. States have also been increasingly active in seeking drug rebates, another key source of funding used by programs, and rebates were the second largest driver of budget growth over the last year. By definition, all eligible jurisdictions 54 in FY 2006 ; receive federal ADAP earmark funding based on a formula, but not all ADAPs receive funding from other sources, which are often dependent on individual state and local planning, policy, and or legislative decisions, as well as resource availability. In FY 2006, two ADAPs received only ADAP earmark funding. The breakdown of other sources of funding across the country was as follows among 51 ADAPs reporting data ; see Chart 25 and Appendix XIII ; : Title II ADAP Supplemental Treatment Grants: 20 ADAPs received funding, 4 did not; Title II Base Funds: 21 ADAPs received funding, 0 did not State General Revenue Support: 40 ADAPs received funding, 11 did not Title I EMA Funds: 12 ADAPs received funding, 9 did not Other State Federal Funds: 14 received funding, 7 did not 12.

COVERED DRUGS ATTACHMENT A ; DRUG CODE 00078-0127-05 00078-0127-06 00172-4360-60 * Southeast Only DRUG NAME Clozaril Tab 100 MG 100s Sandoz ; * Clozaril Tab 100 MG 100s U.D. Sandoz ; * Clzapine Tab 100 MG 100s * Clozpaine Tab 100 MG 500s * Clozaril Tab 25 MG 100s Sandoz ; * Clozaril Tab 25 MG 100s U.D. Sandoz ; * Cloxapine Tab 25 MG 500s * Clozappine Tab 25 MG 100s * Zyprexa Tab 10 MG 60s Lilly ; * Zyprexa Tab 10 MG 100s U.D. Lilly ; * Zyprexa Tab 2.5 MG 60s Lilly ; * Zyprexa Tab 5 MG 100s U.D. Lilly ; * Zyprexa Tab 5 MG 60s Lilly ; * Zyprexa Tab 7.5 MG 100s U.D. Lilly ; * Zyprexa Tab 7.5 MG 60s Lilly ; * Dolophine HCL INJ 10MG ML VL 20 Roxane ; Dolophine HCL INJ 10MG ML VL 20 Roxane ; Dolophine HCL Tab 5 MG 100s Roxane ; Methadone HCL Tab 5 MG Roxane ; Methadone HCL Tab 5 MG Roxane ; Methadone HCL Tab 5 MG Roxane ; Dolophine HCL Tab 10 MG 100s Roxane ; Methadone HCL Tab 10 MG Roxane ; Methadone TAB 40 MG 100s Roxane ; Methadone HCL Tab 10 MG Roxane ; Methadose Tab 10 MG Mallinckrodt ; Methadone HCL Diskets 40 MG 100s Roxane ; Methadone Tab 40 MG 100s Roxane ; Methadone Tab 40 MG 100s Roxane ; Methadose Tab 40 MG Mallinckrodt ; Methadone 10MG 5ML Solution Roxane ; Methadone Oral Conc Sol 10MG ML 946 ML UDL ; Methadone 5MG ML Solution Roxane ; Methadone HCL Tab 10 MG Roxane ; Methadose Tab 5 MG Mallinckrodt ; Methadone 10MG ML Oral Conc 946 ML Roxane ; Methadone Intensol 10MG ML Oral Conc 30 ML Roxane ; Methadone Oral Conc 10MG ML 946 ML Mallinckrodt ; Revia Tab 50 MG Pack 28s Dupont Pharma ; Revia Tab 50 MG 50s Dupont Pharma.